Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes. Issue 8 (18th January 2016)

• Record Type: Journal Article
• Authors: Biester, Torben; Danne, Thomas; Bläsig, Sarah; Remus, Kerstin; Aschemeier, Bärbel; Kordonouri, Olga; Bardtrum, Lars; Haahr, Hanne
• Is Part Of: Pediatric diabetes. Volume 17:Issue 8(2016)
• Page Start: 642
• Page End: 649
• Publication Date: 2016-01-18
• Subjects: adolescents -- children -- insulin degludec – insulin aspart -- pharmacodynamics -- pharmacokinetics; Diabetes in children -- Periodicals; 616.462
• DOI: 10.1111/pedi.12358
• Languages: English
• ISSNs: 1399-543X

Abstract

Abstract : Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of long‐acting insulin degludec and short‐acting insulin aspart. This open‐label, Phase 1 study aimed to determine the pharmacodynamic and pharmacokinetic properties of IDegAsp in children (6–11 yr), adolescents (12–17 yr), and adults (18–65 yr) with type 1 diabetes mellitus (T1DM). Thirty‐eight subjects received single subcutaneous IDegAsp dosing (0.5 U/kg) immediately before a standardized liquid meal (17.3 g carbohydrates/100 mL; adjusted for body weight) followed by plasma glucose (PG) and pharmacokinetic blood sampling for 36 and 57 h, respectively. There were no apparent differences between age groups in PG lowering effect (AUCPG baseline, 0–6 h, meal, SD ), maximum PG excursion (ΔPGmax, meal, SD ), or maximum PG concentration (PGmax, meal, SD ) after the standardized meal. Estimated ratios (ERs) for total exposure (AUCIAsp, 0–12 h, SD ) and maximum concentration (Cmax, IAsp, SD ) of IAsp in IDegAsp were children/adults, 1.69 (95% confidence interval, CI: 1.02; 2.80) and 1.66 (95% CI: 1.10; 2.51); adolescents/adults, 1.14 (95% CI: 0.76; 1.69) and 1.16 (95% CI: 0.84; 1.61). ERs for total exposure (AUCIDeg, 0–∞, SD ) and maximum concentration (Cmax, IDeg, SD ) of IDeg in IDegAsp were children/adults, 1.42 (95% CI: 0.94; 2.16) and 1.38 (95% CI: 1.09; 1.76); adolescents/adults, 1.23 (95% CI: 0.96; 1.58) and 1.16 (95% CI: 0.95; 1.42). IDegAsp was well tolerated across age groups. The fast onset of prandial coverage of IAsp in IDegAsp and the ultra‐long pharmacokinetic properties of IDeg in IDegAsp were preserved in children and adolescents. Exposure to IAsp and IDeg seemed to be higher in children vs. adults, but no differences were observed in PG lowering effect. IDegAsp could be an alternative treatment option in children and adolescents with T1DM.